Therapeutic potential of matrix metalloprotease inhibitors in neuropathic pain

Expert Opin Investig Drugs. 2010 Apr;19(4):455-68. doi: 10.1517/13543781003643486.

Abstract

Importance of the field: Millions of people suffer from neuropathic pain (NP), but the treatment is empirical and results in transient relief in only a few patients. This is primarily because of the poor understanding of the molecular mechanism underlying NP. Following nerve injury, there is a differential and temporal pattern of MMPs expression that coincides with changes in levels of pro-inflammatory cytokines, suggesting that MMPs not only act as mediators for neuroinflammation but might also be directly involved in pain associated with nerve damage.

Areas covered in this review: The present review describes the different mechanisms of NP. The main focus of the review is to highlight the importance of MMPs in NP and their inhibition as a novel approach for treating NP.

What the reader will gain: A comprehensive overview of the role of MMPs in the pathogenesis of NP and the potential of MMP inhibition as a therapeutic intervention for NP.

Take home message: Targeted therapy using specific MMP inhibitors, siRNAs, peptide inhibitors and monoclonal antibodies can provide a better way of treatment by blocking a single MMP and can reduce the side effects of broad-spectrum MMP inhibitors.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials as Topic / trends
  • Humans
  • Matrix Metalloproteinase Inhibitors*
  • Matrix Metalloproteinases / metabolism
  • Neuralgia / drug therapy*
  • Neuralgia / enzymology*
  • Pain / drug therapy
  • Pain / enzymology
  • Protease Inhibitors / pharmacology
  • Protease Inhibitors / therapeutic use*
  • Signal Transduction / drug effects
  • Signal Transduction / physiology

Substances

  • Matrix Metalloproteinase Inhibitors
  • Protease Inhibitors
  • Matrix Metalloproteinases